scholarly journals Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features

2020 ◽  
Vol 9 (3) ◽  
pp. 549-562 ◽  
Author(s):  
Qiufang Liu ◽  
Dazhen Sun ◽  
Nan Li ◽  
Jinman Kim ◽  
Dagan Feng ◽  
...  
2021 ◽  
Vol 11 ◽  
Author(s):  
Guotao Yin ◽  
Ziyang Wang ◽  
Yingchao Song ◽  
Xiaofeng Li ◽  
Yiwen Chen ◽  
...  

2020 ◽  
Vol 10 ◽  
Author(s):  
Min Zhang ◽  
Yiming Bao ◽  
Weiwei Rui ◽  
Chengfang Shangguan ◽  
Jiajun Liu ◽  
...  

2015 ◽  
Vol 29 (9) ◽  
pp. 757-765 ◽  
Author(s):  
Takashi Tanaka ◽  
Takayoshi Shinya ◽  
Shuhei Sato ◽  
Toshiharu Mitsuhashi ◽  
Koichi Ichimura ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Guotao Yin ◽  
Ziyang Wang ◽  
Yingchao Song ◽  
Xiaofeng Li ◽  
Yiwen Chen ◽  
...  

ObjectiveThe purpose of this study was to develop a deep learning-based system to automatically predict epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma in 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT).MethodsThree hundred and one lung adenocarcinoma patients with EGFR mutation status were enrolled in this study. Two deep learning models (SECT and SEPET) were developed with Squeeze-and-Excitation Residual Network (SE-ResNet) module for the prediction of EGFR mutation with CT and PET images, respectively. The deep learning models were trained with a training data set of 198 patients and tested with a testing data set of 103 patients. Stacked generalization was used to integrate the results of SECT and SEPET.ResultsThe AUCs of the SECT and SEPET were 0.72 (95% CI, 0.62–0.80) and 0.74 (95% CI, 0.65–0.82) in the testing data set, respectively. After integrating SECT and SEPET with stacked generalization, the AUC was further improved to 0.84 (95% CI, 0.75–0.90), significantly higher than SECT (p<0.05).ConclusionThe stacking model based on 18F-FDG PET/CT images is capable to predict EGFR mutation status of patients with lung adenocarcinoma automatically and non-invasively. The proposed model in this study showed the potential to help clinicians identify suitable advanced patients with lung adenocarcinoma for EGFR‐targeted therapy.


Sign in / Sign up

Export Citation Format

Share Document